Alaunos Therapeutics (WEK0) Financial Statements
Alaunos Therapeutics Financial Overview
Alaunos Therapeutics's market cap is currently $6.29M. The company's EPS TTM is $-1.95; its P/E ratio is -1.00; Alaunos Therapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 5.00K | $ 10.00K | $ 5.00K | $ 2.92M | $ 398.00K |
| Gross Profit | $ -1.36M | $ -352.00K | $ -4.80M | $ -19.60M | $ -46.88M |
| Operating Income | $ -4.22M | $ -4.81M | $ -34.27M | $ -35.10M | $ -77.55M |
| EBITDA | $ -4.17M | $ -4.68M | $ -30.90M | $ -31.82M | $ -74.97M |
| Net Income | $ -4.18M | $ -4.68M | $ -35.14M | $ -37.73M | $ -78.75M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.39M | $ 1.09M | $ 6.06M | $ 39.06M | $ 76.05M |
| Total Assets | $ 2.97M | $ 2.75M | $ 8.26M | $ 64.94M | $ 94.86M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 20.07M | $ 30.09M |
| Net Debt | $ -1.39M | $ -1.09M | $ -6.06M | $ -18.99M | $ -45.96M |
| Total Liabilities | $ 813.00K | $ 692.00K | $ 1.96M | $ 26.38M | $ 36.81M |
| Stockholders' Equity | $ 2.15M | $ 2.06M | $ 6.31M | $ 38.55M | $ 58.06M |
| Cash Flow | |||||
| Free Cash Flow | $ -2.97M | $ -4.97M | $ -30.34M | $ -29.45M | $ -64.79M |
| Operating Cash Flow | $ -2.87M | $ -4.97M | $ -30.14M | $ -29.23M | $ -61.47M |
| Investing Cash Flow | $ -98.00K | $ 0.00 | $ 1.35M | $ -193.00K | $ -3.32M |
| Financing Cash Flow | $ 3.26M | $ 0.00 | $ -18.14M | $ 6.37M | $ 25.78M |
Currency in USD